ERBB2 and ovarian carcinoma: Thus, this study reveals a new mechanism of crosstalk between AR and HER2/HER3 pathways and opens up novel avenues of targeting and manipulating the NRF2-AR to uncouple and sensitise HER2/HER3 pathways resistant ovarian cancer cells to targeted immunotherapeutics.